BUZZ-Akebia Therapeutics tumbles on deep-discounted $50 mln stock sale

Reuters03-20

** Shares of Akebia Therapeutics AKBA.O down 26.1% at $2.10 before the bell after co raises equity at steep discount

** Cambridge, Massachusetts-based co focused on kidney disease late Weds announced pricing of 25 mln shares at $2 for $50 mln gross proceeds

** Offering priced at 29.6% discount to last sale

** AKBA shares rose ~11% on Weds, capping a four-session winning streak in which they racked up a 68% gain

** On Mar 13, co reported Q4 results and said it expects its anemia drug, branded as Vafseo, to generate $10-$11 mln of net product revs in Q1

** Co to use net offering proceeds to fund working capital and general corporate purposes, including R&D and commercial activities for its products and pipeline candidates, per the SEC prospectus filing

** With ~236.2 mln shares outstanding, per the latest 10-K filing, AKBA has ~$670 mln market cap

** Leerink Partners and Piper Sandler are jt bookrunners for the stock offering

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment